Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen

As its stock price plummeted early this year, what did Massachusetts biotech Epizyme do to try to stop the bleeding?

In a Tuesday filing with the Securities and Exchange Commission (SEC), Epizyme provided an intriguing blow-by-blow of how it tried to resolve its financial woes.